Core Viewpoint - Yifan Pharmaceutical emphasizes the importance of shareholder concerns and market value management, committing to standardized operations and multiple measures to stabilize its market value [2] Group 1 - The company is focused on enhancing its main business profitability [2] - The company aims to optimize its product structure [2] - The company is working on reducing production costs [2] Group 2 - The company is strengthening information disclosure and investor communication [2] - The company believes that its market value will align with its intrinsic value through effective management [2]

Group 1 - The core viewpoint of the article is that Yifan Pharmaceutical is committed to timely disclosure regarding the new regional sales of Yilishu and will communicate investor concerns about its overseas market performance to management [2] Group 2 - Yifan Pharmaceutical responded to investor inquiries on its interactive platform, indicating that it will follow regulations for any new regional market launches of Yilishu [2] - The company acknowledges the importance of investor feedback regarding the overseas market performance of Yilishu [2]

Group 1 - The company, Lu Kang Pharmaceutical (600789.SH), expects to achieve a net profit attributable to shareholders of the parent company between 110 million to 145 million yuan for the fiscal year 2025 [1] - This represents a decrease of 249.62 million to 284.62 million yuan compared to the previous year [1] - The year-on-year decline in net profit is projected to be between 63.26% to 72.13% [1]

Core Viewpoint - The company has signed a strategic cooperation framework agreement with Hangzhou Derui Zhiyao Technology Co., Ltd. to establish a long-term partnership for CDMO projects, emphasizing mutual benefits and complementary advantages [1] Group 1 - The agreement is a framework agreement and does not involve substantial transactions [1] - The agreement does not constitute a related party transaction [1] - The agreement does not fall under the major asset restructuring regulations as per the listed company management measures [1] Group 2 - The signing of the strategic framework agreement does not require approval from the company's board of directors or shareholders [1]

证券时报·数据宝统计显示，泓博医药今日收于48.90元，下跌2.59%，日换手率为11.21%，成交额为6.97 亿元，近5日上涨3.49%。通过对2025年业绩预增50%以上的个股走势进行统计发现，预告发布后当日股 价上涨的占比60.26%，股价发布当日股价涨停的有12家。预告发布后5日股价上涨的占比60.26%。 泓博医药（301230）1月27日发布2025年业绩预增公告，预计实现净利润为3120.00万元~3810.00万元， 净利润同比增长82.64%~123.03%。 资金面上，该股今日主力资金净流出6333.75万元，近5日资金净流出8390.50万元。最新（1月26日）两 融余额3.88亿元，其中，融资余额3.87亿元，环比前一交易日增长2.22%，近5日融资余额累计下降 20.44%。（数据宝） （文章来源：证券时报网） ...

证券之星消息，1月27日化学制药板块较上一交易日下跌0.97%，广生堂领跌。当日上证指数报收于 4139.9，上涨0.18%。深证成指报收于14329.91，上涨0.09%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301089 | 拓新药业 | 34.37 | 7.98% | 18.06万 | | 5.92亿 | | 000952 | 广济药业 | 8.26 | 6.03% | 55.28万 | | 4.36亿 | | 300765 | 新诺威 | 40.93 | 5.41% | 12.05万 | | 4.83亿 | | 603229 | 奧翔药业 | 10.45 | 4.40% | - 36.29万 | | 3.70亿 | | 688176 | 亚斯医药 | 14.56 | 4.30% | 17.36万 | | 2.51亿 | | 301263 | 泰恩康 | 34.45 | 3.30% | 11.27万 | | 3.86亿 | | 688 ...

格隆汇1月27日丨海翔药业(002099.SZ)公布，收到国家药品监督管理局核准签发的地夸磷索钠《化学原 料药上市申请批准通知书》。地夸磷索钠是一种P2Y2受体激动剂，其滴眼液制剂用于干眼症的治疗。 地夸磷索钠作用于结膜上皮及杯状细胞膜上的P2Y2受体，通过上调细胞内的钙离子浓度，促进水分及 黏蛋白的分泌，进而改善干眼病症状。 ...

Core Viewpoint - The approval of the sodium diquafosol raw material drug by the National Medical Products Administration enhances the company's product pipeline and competitiveness, although it will not have a significant short-term impact on performance due to pending GMP inspections and various uncertainties regarding production and sales timing [1] Group 1 - The company has received the approval notice for the sodium diquafosol raw material drug, which is packaged in 5kg barrels and meets drug registration requirements [1] - Sodium diquafosol is a P2Y2 receptor agonist, and its eye drops are used for the treatment of dry eye syndrome, with projected sales of 130.89 million yuan in public hospitals in Chinese cities in 2024 [1] - The approval will enrich the company's product pipeline and enhance its competitiveness in the market [1] Group 2 - The company still needs to pass GMP inspections, which introduces uncertainty regarding the short-term impact on performance [1] - The timing and conditions of production and sales are influenced by multiple factors, leading to further uncertainties [1]

来源：人民日报 马大为在做实验。 中国科学院上海有机化学研究所研究员马大为致力合成生物学研究—— 努力寻找药物合成的最优解（弘扬科学家精神） 马大为（中）在与学生讨论课题。 马大为，1963年生，河南社旗人，中国科学院院士、中国科学院上海有机化学研究所研究员。主要从事 复杂天然产物全合成及构效关系、有机合成方法学和其在合成生物活性分子中的应用等研究。他改进的 乌尔曼反应，解决了碳—杂原子键构建的科学难题，成果广泛应用于新药研发和新材料研制。曾获国家 自然科学奖二等奖、第三届全国创新争先奖、上海市科技功臣奖等。 在中国科学院上海有机化学研究所（以下简称"有机所"），提到马大为，很多人竖起大拇指，他的研究 被一些国际同行评价为"现代药物发现最常用的方法之一"。面对同行的称赞，马大为说："没做什么， 我就是个普通的科研人员。" "不能轻言放弃，要始终有寻找难题答案的勇气" 以上图片均为中国科学院上海有机化学研究所提供 人物小传 除了开展催化偶联反应研究，马大为还将很多时间投入到天然产物（即天然存在的化学成分）全合成和 药物化学研究中。有机所所长胡金波说："从有机合成方法学，到萜类和生物碱类天然产物全合成，再 到特殊 ...

Core Viewpoint - The article emphasizes the commitment of Liaoning Province to improve the business environment by addressing key issues raised by enterprises and the public, implementing a series of measures to enhance service efficiency and regulatory compliance [13][21]. Group 1: Business Environment Improvement - Liaoning Province has launched the "2026 Action Plan for Optimizing the Business Environment," focusing on creating a favorable policy environment, a fair market environment, an efficient administrative environment, a transparent legal environment, and a supportive cultural environment for businesses [13][21]. - The province aims to tackle issues such as weak service awareness, inefficient administrative processes, and corruption, with a strong commitment to improving the overall business climate [5][19]. Group 2: Policy Implementation and Effectiveness - The local government has initiated on-site services for enterprises, such as the retirement approval process at Northeast Pharmaceutical, which has significantly reduced the time and effort required for businesses to navigate bureaucratic procedures [15][16]. - Policies are being designed to be straightforward and easy to understand, with clear standards and timelines for implementation, allowing for immediate benefits to businesses [16][20]. Group 3: Environmental Compliance and Regulation - Liaoning's ecological environment department has introduced a proactive "invitation-style" enforcement inspection to help companies identify and rectify compliance issues before they lead to penalties, shifting the focus from post-incident punishment to preemptive guidance [17][18]. - The province is also enhancing regulatory practices by utilizing technology for remote monitoring and non-intrusive inspections, aiming to streamline compliance processes and reduce unnecessary burdens on businesses [18]. Group 4: Administrative Efficiency in Public Services - A significant reform in the residence permit issuance process has been implemented, reducing the processing time from several days to as little as 5 to 20 minutes, thereby improving service efficiency for residents [19][20]. - The establishment of a closed-loop management mechanism for handling complaints related to the business environment ensures that issues are addressed promptly and effectively, fostering a more transparent and responsive administrative system [20][21].